BNTC BENITEC BIOPHARMA INC revenue, earnings and financials
For the quarter ended March 31, 2026, BENITEC BIOPHARMA INC reported revenue of $0, net income of −$11.9M and diluted EPS of −$0.24; for the fiscal year ended June 2025 revenue was n/a.
BNTC annual revenue and earnings
- Fiscal year ended Jun 2025: revenue n/a, gross profit n/a, operating income −$41.8M, net income −$37.9M (margin n/a), EPS −$1.05
- Fiscal year ended Jun 2024: revenue $0, gross profit n/a, operating income −$22.5M, net income −$21.8M (margin n/a), EPS −$1.22
- Fiscal year ended Jun 2023: revenue $75.0K, gross profit n/a, operating income −$19.1M, net income −$19.6M (margin -26082.7%), EPS −$14.12
- Fiscal year ended Jun 2022: revenue $73.0K, gross profit n/a, operating income −$17.9M, net income −$18.2M (margin -24942.5%), EPS −$37.88
- Fiscal year ended Jun 2021: revenue $59.0K, gross profit n/a, operating income −$13.6M, net income −$13.9M (margin -23528.8%), EPS −$3.23
BNTC quarterly revenue and earnings
- Quarter ended Mar 31, 2026: revenue $0, net income −$11.9M, EPS −$0.24
- Quarter ended Dec 31, 2025: revenue $0, net income −$11.8M, EPS −$0.26
- Quarter ended Sep 30, 2025: revenue $0, net income −$8.97M, EPS −$0.22
- Quarter ended Jun 30, 2025: revenue n/a, net income −$8.81M, EPS −$0.21
- Quarter ended Mar 31, 2025: revenue $0, net income −$14.5M, EPS −$0.38
- Quarter ended Dec 31, 2024: revenue $0, net income −$9.55M, EPS −$0.26
- Quarter ended Sep 30, 2024: revenue $0, net income −$5.06M, EPS −$0.18
- Quarter ended Jun 30, 2024 (from the annual report): revenue $0 (down 100.0% year over year), net income −$4.78M, EPS $4.70
- Quarter ended Mar 31, 2024: revenue $0 (down 100.0% year over year), net income −$4.28M, EPS −$0.23
- Quarter ended Dec 31, 2023: revenue $0 (down 100.0% year over year), net income −$6.80M, EPS −$2.64
- Quarter ended Sep 30, 2023: revenue $0, net income −$5.95M, EPS −$3.05
- Quarter ended Jun 30, 2023 (from the annual report): revenue $7.00K, net income −$4.66M, EPS −$0.13
- Quarter ended Mar 31, 2023: revenue $54.0K (up 12.5% year over year), net income −$4.40M, EPS −$2.67
- Quarter ended Dec 31, 2022: revenue $14.0K (down 44.0% year over year), net income −$5.41M, EPS −$3.34
- Quarter ended Sep 30, 2022: revenue $0, net income −$5.09M, EPS −$7.98
- Quarter ended Jun 30, 2022 (from the annual report): revenue $0, net income −$5.07M, EPS −$36.27
- Quarter ended Mar 31, 2022: revenue $48.0K (up 4700.0% year over year), net income −$3.28M, EPS −$0.40
- Quarter ended Dec 31, 2021: revenue $25.0K, net income −$4.82M, EPS −$0.59
- Quarter ended Sep 30, 2021: revenue $0, net income −$5.05M, EPS −$0.62
- Quarter ended Mar 31, 2021: revenue $1.00K, net income −$3.91M, EPS −$0.82
BNTC cash flow, buybacks and dividends
- Fiscal year ended Jun 2025: operating cash flow −$23.6M, share buybacks n/a
- Fiscal year ended Jun 2024: operating cash flow −$19.4M, share buybacks n/a
- Fiscal year ended Jun 2023: operating cash flow −$18.0M, share buybacks n/a
- Fiscal year ended Jun 2022: operating cash flow −$15.9M, share buybacks n/a
- Fiscal year ended Jun 2021: operating cash flow −$12.8M, share buybacks n/a
BNTC balance sheet
- Jun 30, 2026: cash $180M, total assets $183M, total liabilities $5.61M, shareholders' equity $177M
- Mar 31, 2026: cash $185M, total assets $187M, total liabilities $3.67M, shareholders' equity $183M
- Dec 31, 2025: cash $189M, total assets $191M, total liabilities $3.32M, shareholders' equity $187M
- Sep 30, 2025: cash $94.5M, total assets $96.0M, total liabilities $2.43M, shareholders' equity $93.6M
- Jun 30, 2025: cash $97.7M, total assets $99.6M, total liabilities $2.30M, shareholders' equity $97.3M
- Mar 31, 2025: cash $104M, total assets $105M, total liabilities $7.64M, shareholders' equity $97.6M
- Dec 31, 2024: cash $78.3M, total assets $79.1M, total liabilities $3.13M, shareholders' equity $75.9M
- Sep 30, 2024: cash $67.8M, total assets $68.8M, total liabilities $4.59M, shareholders' equity $64.2M
Is BNTC profitable?
No. BENITEC BIOPHARMA INC lost $41.5M over the last four quarters.
What is BNTC's EPS?
Diluted earnings per share over the last four quarters were −$0.93; −$0.24 in the latest quarter.